Amicus Therapeutics, Inc. provided earnings guidance for the year 2023. For the full-year 2023, the company anticipates total Galafold revenue growth between 12% and 17% at CER driven by continued underlying demand from both switch and treatment-naïve patients, geographic expansion, label extensions, the continued diagnosis of new Fabry patients, and commercial execution across all major markets, including the U.S., EU, U.K., and Japan.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.945 USD | +2.00% | +6.87% | -29.73% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.73% | 2.89B | |
+39.57% | 54.04B | |
+43.57% | 41.96B | |
-1.11% | 41.92B | |
-7.59% | 28.35B | |
+12.83% | 26.35B | |
-22.08% | 19B | |
+7.67% | 13B | |
+28.48% | 12.28B | |
+24.62% | 12.19B |
- Stock Market
- Equities
- FOLD Stock
- News Amicus Therapeutics, Inc.
- Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2023